FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan Haycox

Research Profile

Activities & Behaviors

Geographic Areas

Great Britain

Concepts & Ideas

Procedures

Chemicals & Drugs

Organizations

Drug Industry

Disorders

Human Influenza

Co-author Network

Publications

TOP 3
Alan Haycox
How Much Should the NHS Pay for a QALY?
Mark Parker; Alan Haycox; Jane Graves
Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.
Brian Godman; Solveig Sakshaug; Christian Berg; Björn Wettermark; Alan Haycox
Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan Haycox (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alan Haycox
How Much Should the NHS Pay for a QALY?
PharmacoEconomics 2013;31(5):357-9.
2011: Mark Parker; Alan Haycox; Jane Graves
Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.
PharmacoEconomics 2011;29(8):719-30.
2011: Brian Godman; Solveig Sakshaug; Christian Berg; Björn Wettermark; Alan Haycox
Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.
Expert review of pharmacoeconomics & outcomes research 2011;11(1):121-9.
2009: Alan Haycox
Optimizing decision making and resource allocation in palliative care.
Journal of pain and symptom management 2009;38(1):45-53.
2009: Alan Haycox; Christophe Armand; Susana Murteira; John Cochran; Clément François
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Drugs & aging 2009;26(9):791-801.
2008: Silvio Garattini; Vittorio Bertele'; Brian Godman; Alan Haycox; Björn Wettermark; Lars L Gustafsson
Enhancing the rational use of new medicines across European health care systems.
European journal of clinical pharmacology 2008;64(12):1137-8.
2008: Antonieta Medina Lara; Barbara Nyanzi Wakholi; Agnes Kasirye; Paula Munderi; Christine Watera; David Lalloo; Alan Haycox; Charles F Gilks; Heiner Grosskurth
Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans.
AIDS (London, England) 2008;22 Suppl 1():S123-30.
2008: Alan Haycox; Richard Featherstone
Cost effectiveness of asthma treatment with a breath-actuated inhaler: how has the story changed?
Journal of medical economics 2008;11(3):525-39.
2008: Alan Haycox
Does 'NICE blight' exist, and if so, why?
PharmacoEconomics 2008;26(12):987-9.
2008: Björn Wettermark; Brian Godman; Karolina Andersson; Lars ´Gustafsson; Alan Haycox; Vittorio Bertele
Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.
PharmacoEconomics 2008;26(7):537-50.
2008: Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.
PharmacoEconomics 2008;26(2):91-8.
2007: Ruaraidh A Hill; Angela Boland; Rumona Dickson; Yenal Dündar; Alan Haycox; C McLeod; R Mujica Mota; Tom Walley; Adrian Bagust
Drug-eluting stents: a systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2007;11(46):iii, xi-221.
2007: Alan Haycox
When NICE says no!
PharmacoEconomics 2007;25(12):995-6.
2007: Yenal Dundar; Adrian Bagust; Rumona Dickson; Susanna Dodd; J Green; Alan Haycox; R Hill; C McLeod; Tom Walley
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2007;11(1):1-90.
2006: Yenal Dundar; Susanna Dodd; Rumona Dickson; Tom Walley; Alan Haycox; P R Williamson
Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.
Health technology assessment (Winchester, England) 2006;10(5):iii-iv, ix-145.
2005: Alan Haycox
Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
PharmacoEconomics 2005;23 Suppl 1():3-16.
2004: Stephen J Allsup; Alan Haycox; Martyn Regan; Margot A Gosney
Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial.
Vaccine 2004;23(5):639-45.
2004: R Hill; Adrian Bagust; Ameet Bakhai; Rumona Dickson; Yenal Dündar; Alan Haycox; R Mujica Mota; A Reaney; D Roberts; P Williamson; Tom Walley
Coronary artery stents: a rapid systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2004;8(35):iii-iv, 1-242.
2004: Yenal Dündar; Angela Boland; Judith Strobl; Susanna Dodd; Alan Haycox; Adrian Bagust; J Bogg; Rumona Dickson; Tom Walley
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2004;8(24):iii-x, 1-125.
2004: Alan Haycox
Insulin aspart : an evidence-based medicine review.
Clinical drug investigation 2004;24(12):695-717.
2003: Cyrus R Kumana; M K H Tong; Chun Sang Li; Ian J Lauder; Joseph S K Lee; Maybelle Kou; Tom Walley; Alan Haycox; Tak Mao Chan
Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin.
British journal of clinical pharmacology 2003;56(6):670-8.
2003: Judith Strobl; Ian Enzer; Adrian Bagust; Alan Haycox; Rosalind Smyth; Deborah Ashby; Tom Walley
Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry.
Pharmacoepidemiology and drug safety 2003;12(6):467-73.
2003: Angela Boland; Alan Haycox; Adrian Bagust; L Fitzsimmons
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses.
Health technology assessment (Winchester, England) 2003;7(36):iii, ix-x, 1-99.
2003: Stephen J Allsup; Margot A Gosney; Alan Haycox; Martyn Regan
Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
Health technology assessment (Winchester, England) 2003;7(24):iii-x, 1-65.
2003: Angela Boland; Yenal Dundar; Adrian Bagust; Alan Haycox; R Hill; R Mujica Mota; Tom Walley; Rumona Dickson
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2003;7(15):1-136.
2002: Pamela Whitten; Frances Mair; Alan Haycox; Carl May; Tracy L Williams; Seth Hellmich
Systematic review of cost effectiveness studies of telemedicine interventions.
BMJ (Clinical research ed.) 2002;324(7351):1434-7.
2002: Richard G McWilliams; Janis Martin; Donagh White; Derek A Gould; Peter C Rowlands; Alan Haycox; John Brennan; Geoffrey L Gilling-Smith; Peter L Harris
Detection of endoleak with enhanced ultrasound imaging: comparison with biphasic computed tomography.
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 2002;9(2):170-9.
2001: Stephen J Allsup; Margot A Gosney; Martyn Regan; Alan Haycox; S Fear; F C Johnstone
Side effects of influenza vaccination in healthy older people: a randomised single-blind placebo-controlled trial.
Gerontology 2001;47(6):311-4.
2001: DA Hughes; Adrian Bagust; Alan Haycox; Tom Walley
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.
Health economics 2001;10(7):601-15.
2001: DA Hughes; Adrian Bagust; Alan Haycox; Tom Walley
Accounting for noncompliance in pharmacoeconomic evaluations.
PharmacoEconomics 2001;19(12):1185-97.
2000: Tom Walley; AS Earl-Slater; Alan Haycox; Adrian Bagust
An integrated national pharmaceutical policy for the United Kingdom?
BMJ (Clinical research ed.) 2000;321(7275):1523-6.
1999: Alan Haycox; Adrian Bagust; Tom Walley
Importance of health economics must be recognised when trials are designed.
BMJ (Clinical research ed.) 1999;318(7199):1696-7.
1999: Alan Haycox; Adrian Bagust; Tom Walley
Clinical guidelines-the hidden costs.
BMJ (Clinical research ed.) 1999;318(7180):391-3.